Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
|Articles|January 30, 2021
- January 2021
- Volume 89
- Issue 1
CE: PCSK9 Inhibitors: The Role of the Pharmacist in Identifying and Addressing the Clinical and Economic Barriers for the Treatment of Hyperlipidemia
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Advertisement
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
- Examine the pathogenesis, incidence, risk factors, and current standards of care for the treatment of hyperlipidemia
- Explore the efficacy and safety data associated with the use of PCSK9 inhibitors and their clinical benefits in the treatment of hyperlipidemia
- Discuss the current hyperlipidemia management guidelines from the American Heart Association and the American College of Cardiology
- Identify the role of the pharmacist in patient education and recognizing and educating patients who may be ideal candidates or currently on PCSK9 inhibitors for the treatment of hyperlipidemia through motivational interviewing
FACULTY
Paul B. Shaw, PharmD, BCPS, BCCP
Clinical Pharmacy Specialist — Cardiology, Kaiser Permanente of Colorado, Clinical Assistant Professor – University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Lafayette, Colorado
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: December 18, 2020
EXPIRATION DATE: January 18, 2022
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.5 hours
FEE: This lesson is offered for free at
Articles in this issue
over 5 years ago
Let’s Take Care of Ourselves This Seasonover 5 years ago
Spot Heart Failure a Mile Awayover 5 years ago
Legislation Aims to Protect Children With Severe Allergiesover 5 years ago
Managing Inventory Well Is a Critical Functionover 5 years ago
OTC Cases: Influenzaover 5 years ago
Pharmacists Play an Essential Role in Managing Hypertensionover 5 years ago
Interactives: Case Studies (January 2021)over 5 years ago
Chronic Conditions Affect Brain FunctionAdvertisement
Related to this article
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
What Different Communities Taught Me About Patient Care
4
Patients Report Early, Sustained Functional Gains With First-Line Zongertinib in HER2-Mutant NSCLC
5